论文部分内容阅读
目的各种病原引起的慢性肝病中，肝纤维化是导致肝硬变的共同途径，多数学者认为血清Ⅳ型胶原（Ⅳ－C）和透明质酸（HA）联合检测能反映肝纤维化的动态过程[1]．目前临床治疗肝纤维化及肝硬变缺乏特异药物．本研究的目的是通过观察丹参加前列腺素E2（PGE2）治疗肝硬变患者前后血清Ⅳ－C，HA含量变化探讨其临床作用．对象和方法研究对象为本院乙型肝炎后肝硬变患者60例，肝硬变诊断标准符合1990年全国肝炎会议制订的诊断标准．健康对照为本院血库健康献血员36例．血清Ⅳ-C测定采用双单克隆抗体EIA法，HA含量采用放射免疫分析法测定．将60例肝硬变患者随机分2组．对照组30例，用维生素C2．5g加10％葡萄糖250mL中静点，实验组30例，上述治疗加丹参和PGE2，丹参注射液14mL加10％葡萄糖250mL中静点，PGE2100mL加10％葡萄糖250mL中静点，1次／d，共28d，再测定血清Ⅳ-C，HA含量．结果60例肝硬变患者血清Ⅳ-C，HA含量明显高于36名健康人（P＜0．001）．肝硬变患者中实验组肝功ChildA，B两级患者血清Ⅳ-C，HA含量治疗后显著下降，与治疗前相比差异有显著性（P＜0．05）．肝功C级患者血清Ⅳ-C，HA治疗后下降不明显，与治疗前相比无显著性差异（P＞0．05）．结论①联合检测Ⅳ-C，HA有利于肝纤维化程度的判断．②丹
Aims Liver fibrosis is the common pathway leading to cirrhosis in chronic liver diseases caused by various pathogens. Most scholars believe that the combined detection of serum type Ⅳ collagen (Ⅳ-C) and hyaluronic acid (HA) can reflect the dynamic changes of liver fibrosis Process [1]. The current clinical treatment of liver fibrosis and cirrhosis lack of specific drugs. The purpose of this study was to investigate the clinical effect of Danshen plus prostaglandin E2 (PGE2) on the changes of serum levels of Ⅳ-C and HA in patients with cirrhosis. Subjects and methods were studied in our hospital, 60 cases of post-hepatitis B cirrhosis, liver cirrhosis diagnostic criteria in line with the 1990 national hepatitis meeting to develop diagnostic criteria. Health control for the hospital blood bank health blood 36 cases. Serum IV-C assay using dual monoclonal antibody EIA method, HA content was determined by radioimmunoassay. Sixty patients with cirrhosis were randomly divided into two groups. The control group of 30 cases, with vitamin C2.5g plus 10% glucose 250mL in the static point, the experimental group of 30 patients with the above treatment plus Salvia and PGE2, Salvia injection 14mL plus 10% glucose 250mL in the static point, PGE2100mL plus 10% glucose 250mL In the static point, 1 times / d, a total of 28d, and then measured serum levels of Ⅳ-C, HA. Results The serum levels of Ⅳ-C and HA in 60 patients with cirrhosis were significantly higher than those in 36 healthy people (P <0.001). The serum levels of Ⅳ-C and HA in patients with liver cirrhosis and liver function in patients with liver cirrhosis were significantly decreased after treatment, which were significantly different from those before treatment (P <0.05). Serum levels of C-Ⅳ and C-HA in patients with liver function grade C did not decrease significantly after treatment, and there was no significant difference between before and after treatment (P> 0.05). Conclusions ① The joint detection of Ⅳ-C, HA is helpful to judge the degree of liver fibrosis. ② Dan